Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Impact of Care Transition on Medication Adherence in Cardiac Patients

Condition:   Acute Coronary Syndrome
Sponsor:   King's College London
Not yet recruiting - verified June 2015

The Association Between Central Aortic Blood Pressure Indices and Severity of Coronary Artery Disease

Condition:   Coronary Artery Disease
Sponsor:   Government Medical College, Kozhikode
Completed - verified June 2015

Active Clearance Technology (ACT) II German Multicenter Trial

Condition:   Heart Surgery
Intervention:   Device: Blood drainage post cardiac surgery using PleuraFlow System
Sponsors:   Prof. Dr. Theodor Fischlein;   ClearFlow, Inc.
Not yet recruiting - verified June 2015

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Not yet recruiting - verified May 2015

Acute Lung Injury After Cardiac Surgery: Pathogenesis

Conditions:   Acute Lung Injury;   Metabolic Disturbances;   Inflammation;   Coagulation; Intravascular;   Postoperative; Dysfunction Following Cardiac Surgery
Intervention:   Other: No intervention
Sponsors:   Aalborg Universitetshospital  ;   Aalborg University
Completed - verified June 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Conditions:   Acute Leukemia;   Myelodysplasia
Interventions:   Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Not yet recruiting - verified June 2015

PPV to Guide Fluid Management in the PICU

Conditions:   Sepsis;   Systemic Inflammatory Response Syndrome
Intervention:   Device: Automated Pulse Pressure Variation
Sponsor:   University of North Carolina, Chapel Hill
Enrolling by invitation - verified June 2015

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2015

Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?

Condition:   Acute Coronary Syndome
Interventions:   Other: Blood Test;   Other: EndoPAT - endothelial assessment
Sponsor:   Jennifer Rossington
Recruiting - verified June 2015

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis II;   Mucopolysaccharidosis VI;   Mucopolysaccharidosis VII;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Glycoprotein Metabolic Disorders;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy;   Peroxisomal Disorders;   Osteopetrosis;   Sphingolipidosis;   Gangliosidosis;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann Pick B;   Niemann Pick C Subtype 2;   I-cell Disease
Interventions:   Procedure: blood stem cell transplant;   Drug: Rabbit Anti-Thymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A (CSA);   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte-Colony Stimulating Factor (G-CSF);   Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Drug: N-acetylcysteine;   Drug: Celecoxib;   Drug: Vitamin E;   Drug: Alpha Lipoic Acid
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2015

Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI

Condition:   Non ST Segment Elevation Acute Coronary Syndrome
Intervention:   Drug: ticagrelor
Sponsor:   General Hospital of Chinese Armed Police Forces
Recruiting - verified January 2015

Modafinil and Cognitive Function in POTS

Condition:   Postural Tachycardia Syndrome
Interventions:   Drug: Placebo;   Drug: Modafinil;   Drug: Propranolol
Sponsor:   Vanderbilt University
Recruiting - verified June 2015

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Efficacy and Safety Study of Ticagrelor

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsor:   General Hospital of Chinese Armed Police Forces
Recruiting - verified March 2015

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Pancytopenia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2015

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions:   Adult Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Chronic Myelomonocytic Leukemia-1;   Chronic Myelomonocytic Leukemia-2;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide;   Drug: Vorinostat
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified March 2015

Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation

Conditions:   Non ST Segment Elevation Myocardial Infarction;   Unstable Angina
Intervention:   Drug: Enoxaparin
Sponsor:   Eurofarma Laboratorios S.A.
Terminated - verified June 2015

Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients

Condition:   Septic Shock
Interventions:   Drug: Dobutamine;   Drug: Placebo
Sponsor:   Pontificia Universidad Catolica de Chile
Completed - verified June 2015

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV;   Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV;   Drug: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
Sponsor:   Bayer
Completed - verified June 2015

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions:   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2015

A Clinical Trial of IntensiVE Dialysis

Conditions:   Renal Replacement Therapy;   Renal Dialysis;   End Stage Kidney Disease;   End Stage Renal Disease;   Uremia
Intervention:   Procedure: haemodialysis
Sponsors:   The George Institute;   National Health and Medical Research Council, Australia;   Baxter Healthcare Corporation
Completed - verified June 2013

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2015

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting - verified June 2015

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Hematologic Neoplasms;   Neural Tube Defects;   Myeloproliferative Disorders
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Biological: T-Rapa cell DLI;   Procedure: T cell DLI;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2014

The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction

Conditions:   Coronary Disease;   Ventricular Dysfunction, Left
Interventions:   Drug: Ivabradine;   Drug: Placebo
Sponsor:   Institut de Recherches Internationales Servier
Completed - verified June 2015

Get CardioSmart

You're Invited